Stock Information
Halozyme Therapeutics Inc (HALO)
Ticker Symbol: HALO
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $7,583.83 mil
Piotroski score: 5
PE Ratio: 24.2901
EPS (TTM): 2.4916
Revenue (TTM): $11.87 M
Dividend Yield: N/A%
ROE: 92.67%
Latest News
-
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
Fri, May 8, 2026 12:05 PM
-
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Thu, May 7, 2026 1:00 PM
-
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
Thu, May 7, 2026 12:50 PM
-
Halozyme Therapeutics Signs License Agreement With GSK For ENHANZE Drug Delivery Technology To Develop, Commercialize Subcutaneous Administration Of Multiple Oncology Targets
Thu, May 7, 2026 9:07 AM
-
Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Wed, May 6, 2026 1:15 PM
-
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Wed, May 6, 2026 12:00 PM
-
Halozyme Therapeutics AGM: Shareholders Elect Directors as CEO Torley Raises 2026 Guidance
Wed, May 6, 2026 1:35 AM
-
Halozyme Therapeutics: The Royalty Engine Is Becoming A Drug-Delivery Toll Road
Wed, May 6, 2026 12:54 AM
-
Halozyme (HALO) Rated Buy on Strong Royalty Growth
Sat, May 2, 2026 5:51 PM
-
How Investors Are Reacting To Halozyme Therapeutics (HALO) Hiring Big-Pharma Veteran Darren Snellgrove As CFO
Sat, May 2, 2026 1:15 PM
Key Financials
Financial data not available
